[ad_1]
NEW YORK, January 22, 2019 / PRNewswire / – PrimeVax Immuno-Oncology, Inc. announced today that the company had just signed an exclusive worldwide license with the US Army Medical Equipment Development Business, Fort. Detrick, MD, USAMMDA, authorizing PrimeVax to use the dengue virus strain # 1 45AZ5 for the treatment of cancer.
"It's an unprecedented gesture," says Dr. Kenneth Eckels, PhD, former head of the bioproduction pilot facility of WRAIR. "For decades, we have developed many candidate vaccines for dengue fever for human testing purposes, but this is the first time anyone uses them for cancer treatment."
PrimeVax's new therapeutic approach combines the dengue virus with dendritic cell therapy. The FDA recently authorized PrimeVax to begin its clinical trial with its dendritic cells.1
"We hope that history considers that it is a turning point in the oncology industry," he said. Tony Chen, CEO of PrimeVax. "Because dengue affects the body in a very different way from other viruses, its immunostimulatory properties make it attractive as an anti-cancer agent." In addition, the US military has already produced data on human safety in humans. These two factors give us confidence We are honored to have the opportunity to use the US Army dengue virus to treat cancer patients. "
For this clinical trial, PrimeVax will continue to treat patients with metastatic melanoma after the failure of standard therapies.
With the license agreement signed with the US military, PrimeVax is now working with the FDA on how to administer the virus. They are also preparing the site for clinical trials. Once these two activities are completed, they will recruit patients.
about us
PrimeVax Immuno-Oncology, Inc. focuses on the development of personalized immunotherapy with its PV-001 platform. The goal of the platform is to enable a cancer treatment program once a week for many types of cancer. The PV-001 simultaneously exploits innate and adaptive immune responses of the body to trigger T cell activation, NK and other immunotherapeutic effects. The company was founded in 2015 and will conduct clinical trials on humans in 2019. The first indications to target include metastatic melanoma, triple negative bad cancer and glioblastoma.
List of clinical trials of PrimeVax on clinicaltrials.gov.
Contact:
PrimeVax Immuno-Oncology, Inc.
Tony Chen
CEO
[email protected]
1https://www.prnewswire.com/news-releases/primevax-immuno-oncology-receives-ind-permission-from-fda-300773453.html
SOURCE PrimeVax Immuno-Oncology, Inc.
Source link
